Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Medicines for Europe Issues 2017 Biosimilar Market Review

by | Sep 13, 2017

Eleven years after the launch of the first biosimilar product in EU, we are now in a position to calibrate our biosimilar market expectations with market experience, rather than extrapolating them using educated guess-work.

Biosimilar and biologics companies doing so will be interested in the Medicines for Europe (formerly the EGA) Biosimilars Medicine EU Market Report 2017 published yesterday.

For EU member states plus Iceland, Norway, Switzerland and Turkey, the Medicines for Europe EU Market Report sets out the following information on a country-by-country basis and product-by-product basis (for on market biosimilars to somatropin, epoetin, filgrastim, infliximab, follitropin alfa, insulin glargine, etanercept, and enoxaparin sodium):

  • Biosimilar availability & setting;

  • Biosimilar pricing & reimbursement;

  • Tendering processes;

  • INN prescribing;

  • Biosimilar prescription practices & government mandate/supportive measures;

  • Biosimilar substitution; and

  • Patient co-payments.

The Biosimilars Medicines EU Market Report was preceded by the EU Market Report May 2017 prepared by IMS/Quintiles at the request of the EU Commission and published on 5 May 2017.  In the May 2017 IMS Report, the following 4 key observations were made for EU:

  1. Biosimilars increase price competition.

  2. Lowering the price of the referenced product can limit biosimilar market penetration.

  3. There is a first to market advantage in biosimilars markets.

  4. Biosimilars have the potential to improve patient access of the total market.

Whilst observations (1) and (2) would be of no surprise to industry, (3) and (4) may come as a surprise to new players.  As the global biosimilars industry is still immature, interested companies will continue to recalibrate their local market expectations for years to come.

Naomi Pearce

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (AU, NZ)

Naomi is the founder of Pearce IP, and is one of Australia’s leading IP practitioners.   Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 25 years’ experience, and a background in molecular biology/biochemistry.  Ranked in virtually every notable legal directory, highly regarded by peers and clients, with a background in molecular biology, Naomi is renown for her successful and elegant IP/legal strategies.

Among other awards, Naomi is ranked in Chambers, IAM Patent 1000, IAM Strategy 300, is a MIP “Patent Star”, and is recognised as a WIPR Leader for patents and trade marks. Naomi is the 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology client choice award recipient for Life Sciences, the 2022 Asia Pacific Women in Business Law “Patent Lawyer of the Year” and the 2021 Lawyers Weekly Women in Law SME “Partner of the Year”.  Naomi is the founder of Pearce IP, which commenced in 2017 and won 2021 “IP Team of the Year” at the Australian Law Awards.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News